Inactivation of NF-κB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells

Breast Cancer Research and Treatment

Volumn 112, Issue 1, 2008, Pages 53-62

  Domingo Domènech, Josep ^a   Pippa, Raffaella ^b   Tápia, Marian ^a   Gascón, Pere ^a   Bachs, Oriol ^b   Bosch, Marta ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Apoptosis; Breast cancer; HDAC inhibitor; NF B; Proteasome inhibition; SAHA

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P27; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRICHOSTATIN A; VORINOSTAT; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CASPASE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; I KAPPA B; LEUPEPTIN; LUCIFERASE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NITRILE; SULFONE; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE DISRUPTION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETIC TRANSFECTION; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASES; COLONY-FORMING UNITS ASSAY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; I-KAPPA B PROTEINS; LEUPEPTINS; LUCIFERASES; MEMBRANE POTENTIAL, MITOCHONDRIAL; NF-KAPPA B; NITRILES; SULFONES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 52949120373     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9837-8     Document Type: Article

References (33)

1. MH Kuo 1998 Roles of histone acetyltransferases and deacetylases in gene regulation Bioessays 20 8 615 626
2. Glozak MA et al (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23
3. MF Fraga 2005 Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat Genet 37 4 391 400
4. RW Johnstone 2002 Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat Rev Drug Discov 1 4 287 299
5. M Karin 2004 The IKK NF-kappa B system: a treasure trove for drug development Nat Rev Drug Discov 3 1 17 26
6. BB Aggarwal 2004 Nuclear factor-kappaB: the enemy within Cancer Cell 6 3 203 208
7. J Domingo-Domenech 2006 Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity Clin Cancer Res 12 18 5578 5586
8. LF Chen 2004 Shaping the nuclear action of NF-kappaB Nat Rev Mol Cell Biol 5 5 392 401
9. LF Chen 2002 Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB EMBO J 21 23 6539 6548
10. R Kiernan 2003 Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65 J Biol Chem 278 4 2758 2766
11. L Chen 2001 Duration of nuclear NF-kappaB action regulated by reversible acetylation Science 293 5535 1653 1657
12. MW Mayo 2003 Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway J Biol Chem 278 21 18980 18989
13. PM Voorhees 2003 The proteasome as a target for cancer therapy Clin Cancer Res 9 17 6316 6325
14. J Adams 2003 The proteasome: structure, function, and role in the cell Cancer Treat Rev 29 Suppl 13 9
15. EB Traenckner 1994 A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B EMBO J 13 22 5433 5441
16. Richardson PG et al (2006) Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 5733-5747
17. J Codony-Servat 2006 Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells Mol Cancer Ther 5 3 665 675
18. CH Yang 2006 Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits Ann Oncol 17 5 813 817
19. M Venkatraman 2005 Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis Mol Carcinog 44 1 51 59
20. UK Laemmli 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 5259 680 685
21. E Adam 2003 Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha Mol Cell Biol 23 17 6200 6209
22. J Adams 2002 Development of the proteasome inhibitor PS-341 Oncologist 7 1 9 16
23. K Brown 1995 Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation Science 267 5203 1485 1488
24. L Huang 2000 Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment Mol Med 6 10 849 866
25. PC Cogswell 2000 Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3 Oncogene 19 9 1123 1131
26. S Ghosh 2002 Missing pieces in the NF-kappaB puzzle Cell 109 Suppl S81 S96
27. M Adachi 2004 Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells Clin Cancer Res 10 11 3853 3862
28. M Giuliano 1999 The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells Cancer Res 59 21 5586 5595
29. XY Pei 2004 Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clin Cancer Res 10 11 3839 3852
30. Y Dai 2005 Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation Mol Cell Biol 25 13 5429 5444
31. Z Xia 1995 Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 5240 1326 1331
32. WK Kelly 2005 Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid Nat Clin Pract Oncol 2 3 150 157
33. VM Richon 2000 Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc Natl Acad Sci USA 97 18 10014 10019